http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4213911-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1d54c08eeb8540176be204d4fb87ef3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J9-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00 |
| filingDate | 1978-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1980-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6fac8bcc79f5d8d550f42f6b15d85ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_456d33555559de0cc39d6a9aedfabe73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5722730c9128b54f39a67d17b762e6e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b17f273a5b218c4b8b6271b4188ad4ff |
| publicationDate | 1980-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4213911-A |
| titleOfInvention | Process for preparing high-melting chenodeoxycholic acid |
| abstract | A process for preparing a high-melting form of CDCA having a melting point of at least about 160 DEG C. is disclosed which comprises the steps of: (a) suspending at least one form of CDCA having a melting point of below 160 DEG C. in a non-aromatic liquid hydrocarbon, preferably cyclohexane, to form a suspension having a boiling point of at least 65 DEG C.; (b) heating the suspension to a sufficiently high temperature of between about 65 DEG and about 140 DEG C., preferably between about 75 DEG and about 100 DEG C., during a sufficiently long period of time for converting substantially all of the CDCA into the high-melting form; (c) recovering the high-melting form of CDCA from the suspension. Low-melting amorphous and/or crystalline forms of CDCA, as well as CDCA-solvent inclusion complexes can be treated in the above-described process. The high-melting CDCA is obtained in form of a substantially granular powder, which is suitable to be formulated into therapeutical compositions. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4337206-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103044512-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102453071-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4316849-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4499020-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102453071-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103012534-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103012534-A |
| priorityDate | 1978-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.